MG
Therapeutic Areas
Roivant Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Brepocitinib | Dermatomyositis | Phase 3 |
| IMVT-1402 | Autoimmune Diseases (e.g., Thyroid Eye Disease, Myasthenia Gravis) | Phase 2/3 |
| Mosliciguat | Pulmonary Diseases (e.g., PAH) | Phase 2 |
| VTAMA® (tapinarof) | Plaque Psoriasis | Approved |
Leadership Team at Roivant Sciences
AG
Alex Gasner
EVP, Roivant Health
EV
Eric Valeur
Vice President, Head of Drug Discovery
DG
Daniel Gold
Director